Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Dychter · SciRah

Researcher profile · Semantic Scholar

S. Dychter

Share profile

S. Dychter — researcher profile on SciRah

h-index: 16
Works: 33
Citations: 2,085

Most-cited papers

Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors
J. Desai, L. Yassa, Ellen Marqusee, S. George +7 more
2006Annals of Internal Medicine393 citations
Semantic Scholar
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
E. Pujade-Lauraine, K. Fujiwara, J. Ledermann, A. Oza +17 more
2021The Lancet Oncology326 citations Open access
Semantic Scholar
Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer
S. Hingorani, William P. Harris, J. Beck, B. Berdov +11 more
2016Clinical Cancer Research306 citations Open access
Semantic Scholar
Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine
E. Moreira, N. Kitchin, Xia Xu, S. Dychter +28 more
2022New England Journal of Medicine270 citations Open access
Semantic Scholar
Intravenous Therapy: A Review of Complications and Economic Considerations of Peripheral Access
S. Dychter, David A. Gold, Deborah Carson, M. Haller
2012Journal of Infusion Nursing219 citations
Semantic Scholar
High incidence and clinical course of aggressive skin cancer in heart transplant patients: a single-center study.
R. Adamson, E. Obispo, S. Dychter, W. Dembitsky +9 more
1998Transplantation Proceedings78 citations
Semantic Scholar
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours
J. Infante, R. Korn, L. Rosen, P. LoRusso +9 more
2017British Journal of Cancer73 citations Open access
Semantic Scholar
Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study design.
E. Pujade-Lauraine, K. Fujiwara, S. Dychter, G. Devgan +1 more
2018Future Oncology69 citations Open access
Semantic Scholar
Subcutaneous Drug Delivery: A Route to Increased Safety, Patient Satisfaction, and Reduced Costs
S. Dychter, David A. Gold, M. Haller
2012Journal of Infusion Nursing65 citations
Semantic Scholar
Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: Primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial
E. Pujade-Lauraine, K. Fujiwara, J. Ledermann, A. Oza +17 more
2019Gynecologic Oncology64 citations
Semantic Scholar
Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration
S. Rosengren, S. Dychter, M. Printz, Lei Huang +9 more
2015AAPS Journal56 citations Open access
Semantic Scholar
Sunitinib-related thyroid dysfunction: A single-center retrospective and prospective evaluation.
P. Schoeffski, P. Wolter, U. Himpe, S. Dychter +5 more
2006Journal of Clinical Oncology37 citations
Semantic Scholar
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers
M. Printz, S. Dychter, E. Denoia, R. Harrigan +5 more
2020Current Therapeutic Research24 citations Open access
Semantic Scholar
Tolerability and pharmacokinetic properties of ondansetron administered subcutaneously with recombinant human hyaluronidase in minipigs and healthy volunteers.
S. Dychter, R. Harrigan, Jesse Bahn, M. Printz +5 more
2014Clinical Therapeutics22 citations
Semantic Scholar
Long-term outcome with the use of OKT3 induction therapy in heart transplant patients: a single-center experience.
R. Adamson, E. Obispo, S. Dychter, W. Dembitsky +9 more
1998Transplantation Proceedings20 citations
Semantic Scholar
A real-world study on characteristics, treatments and outcomes in US patients with advanced stage ovarian cancer
D. Beachler, F. Lamy, L. Russo, Devon H. Taylor +6 more
2020Journal of Ovarian Research18 citations Open access
Semantic Scholar
Comparison of the tolerability of recombinant human hyaluronidase + normal saline and recombinant human hyaluronidase + lactated ringer's solution administered subcutaneously: A phase IV, double-blind, randomized pilot study in healthy volunteers.
S. Dychter, D. Ebel, Tonya R. Mead, R. Yocum
2009Current Therapeutic Research15 citations Open access
Semantic Scholar
Economic Burden of Acute Graft-Versus-Host Disease (GvHD) Following Allogeneic Hematopoietic Cell Transplant (HCT) for Hematologic Malignancies
W. Grubb, S. Huse, N. Alam, S. Dychter +3 more
201611 citations
Semantic Scholar
Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Subcutaneous (SC) Cinryze® (C1 inhibitor (C1 INH) with Recombinant Human Hyaluronidase (rHuPH20) in Subjects with Hereditary Angioedema (HAE)
J. Schranz, R. Levy, W. Lumry, M. Manning +6 more
20127 citations Open access
Semantic Scholar
Targeting hyaluronan (HA) in tumor stroma: Interim safety and translational evaluation of pegylated hyaluronidase (PEGPH20) in patients (pts) with advanced solid tumors-A focus on gastrointestinal malignancies.
J. Infante, R. Ramanathan, M. Borad, L. Rosen +8 more
2012Journal of Clinical Oncology6 citations
Semantic Scholar
Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration
S. Rosengren, S. Dychter, M. Printz, Lei Huang +9 more
2015AAPS Journal4 citations Open access
Semantic Scholar
LBA-02High Response Rate and PFS with PEGPH20 added to Nab-Paclitaxel/Gemcitabine in Stage IV Previously Untreated Pancreatic Cancer Patients with High-HA Tumors: Interim Results of a Randomized Phase 2 Study
A. Hendifar, S. Hingorani, W. Harris, T. Seery +4 more
20154 citations Open access
Semantic Scholar
Phase 1b Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer
S. Hingorani, W. Harris, J. Beck, B. Berdov +12 more
20152 citations
Semantic Scholar
PP 60 Targeting hyaluronan in tumor stroma. Interim translational and biomarker evaluations of pegylated hyaluronidase (PEGPH20) in animal models and patients with advanced solid tumors
S. Dychter, R. Ramanathan, J. Infante, L. Rosen +6 more
20112 citations
Semantic Scholar
Abstract PD10-03: Subgroup analyses of VERITAC-2: A phase 3 trial of vepdegestrant, a PROTAC estrogen receptor (ER) degrader, versus fulvestrant in ER-positive/ human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (aBC)
E. Hamilton, M. de Laurentiis, K. Jhaveri, X. Hu +17 more
2026Clinical Cancer Research1 citations
Semantic Scholar
Avelumab Alone or in Combination with Chemotherapy vs Chemotherapy Alone in Platinum-Resistant or Platinum-Refractory Ovarian Cancer (JAVELIN Ovarian 200): A Randomised, Open-Label, Phase 3 Study
E. Pujade-Lauraine, K. Fujiwara, J. Ledermann, A. Oza +17 more
2020Social Science Research Network1 citations
Semantic Scholar
Erratum to: Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration
S. Rosengren, S. Dychter, M. Printz, Lei Huang +9 more
2015AAPS Journal1 citations Open access
Semantic Scholar
Abstract 2672: Phase 1 pharmacokinetics (PK) & pharmacodynamics (PD) of PEGylated hyaluronidase PH20 (PEGPH20) in patients with solid tumors
D. Maneval, R. Ramanathan, J. Infante, L. Rosen +10 more
20121 citations
Semantic Scholar
Abstract PS2-07-24: Circulating tumor DNA (ctDNA) biomarker analyses of a phase 1/2 study evaluating vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in ER-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (aBC)
S. Wander, H. Han, E. Hamilton, S. Hurvitz +9 more
2026Clinical Cancer Research0 citations
Semantic Scholar
Erratum to: Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration
S. Rosengren, S. Dychter, M. Printz, Lei Huang +9 more
2015AAPS Journal0 citations Open access
Semantic Scholar
Abstract B35: Hyaluronan (HA) accumulation in tumors predicts response to pegylated rHuPH20 hyaluronidase (PEGPH20) in human tumors: A biomarker strategy.
P. Jiang, R. Ramanathan, J. Infante, C. Thompson +4 more
20110 citations
Semantic Scholar
Biotech case studies: Building collaborative relationships
S. Dychter, M. Krupp, P. J. Pokros
20030 citations
Semantic Scholar
Intention to Transplant Survival. Is This a More Accurate Predictor of the Survival Probabilities of Patients After They Are Accepted for Cardiac Transplantation
R. Adamson, E. Obispo, S. Dychter, M. Ruvalcaba +7 more
19980 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

G. Frost×9
Invite
G. Frost — researcher profile on SciRah
P. Jiang×8
Invite
P. Jiang — researcher profile on SciRah
M. Printz×7
Invite
M. Printz — researcher profile on SciRah
D. Maneval×7
Invite
D. Maneval — researcher profile on SciRah

×7

Invite

B. Sugarman — researcher profile on SciRah

Invite

J. Infante — researcher profile on SciRah

R. Ramanathan×5

Invite

R. Ramanathan — researcher profile on SciRah

E. Pujade-Lauraine×4

Invite

E. Pujade-Lauraine — researcher profile on SciRah

Invite

K. Fujiwara — researcher profile on SciRah

Invite

B. Monk — researcher profile on SciRah

Invite

H. Shepard — researcher profile on SciRah

Invite

L. Rosen — researcher profile on SciRah